Buchanan's Corporate team of Rajiv Khanna, Shareholder and Daniel Richey, Associate, worked with client Sonnet Bio Therapeutics, an oncology-focused biotechnology company developing innovative targeted biologic drugs, to complete Sonnet's acquisition agreement with Relief Therapeutics Holding SA (SIX: RLF) to develop atexakin alfa through the acquisition of its subsidiary, Relief Therapeutics SA, via a share exchange transaction. Read Sonnet's news release for more information.